Pharma Focus Asia
KP - Sustainable Packaging Solutions

German Merck Plans US$107.67 million Plant in China

Merck KGaA plans to construct a new plant in China to manufacture diabetes drugs and address critical healthcare needs of the Chinese population.


The new plant is planned to be built in Shaghai, China covering an area of 40,000 square meters. The plant will have a room for a 20,000-square-meter expansion.


The US$107.67 million (€80 million) plant will manufacture diabetes drugs namely Glucophage, Concor, Euthyrox and also drugs for heart and thyroid conditions.


The construction work is scheduled to start in September 2014 and expected to be completed in 2016. Merck plans to start commercial production in 2017.

Specifications Table:

  • Company Name
  • Merck KGaA
  • Location
  • Shanghai, China
  • Construction Type
  • New PLant
  • Date of Start
  • September 2014
  • Date of Completion
  • 2016
  • Estimated Investment:
  • US$107.67 million (€80 million)
  • Key players
  • Sponsors/Partners
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?